Hypophysitis in the era of immune checkpoint inhibitors and immunoglobulin G4-related disease

References

• Caturegli P. Autoimmune hypophysitis. Endocr Rev. 2005;26(5):599–614.
   PubMed Web of Science ®Google Scholar
• Bellastella G, Maiorino MI, Bizzarro A, et al. Revisitation of autoimmune hypophysitis: knowledge and uncertainties on pathophysiological and clinical aspects. Curr Opin Endocrinol Diabetes Obes. 2016;19:625–642.
   Google Scholar
• Prete A, Salvatori R (2018). Hypophysitis. Endotext NCBI Bookshelf.
   Google Scholar
• Ahmed SR, Aiello DP, Page R, et al. Necrotizing infundibulo-hypophysitis: a unique syndrome of diabetes insipidus and hypopituitarism. Jcem. 1993;76(6):1499–1504.
   PubMed Web of Science ®Google Scholar
• Gutenberg A, Caturegli P, Metz I, et al. Necrotizing infundibulo-hypophysitis: an entity too rare to be true? Pituitary. 2011;15:202–208.
   Web of Science ®Google Scholar
• Caturegli P, Iwama S. From Japan with love: another tessera in the hypophysitis mosaic. Jcem. 2013;98(5):1865–1868.
   PubMed Web of Science ®Google Scholar
• Caturegli P, Lupi I, Landek-Salgado M, et al. Pituitary autoimmunity: 30 years later. Autoimmun Rev. 2008;7:631–667.
   PubMed Web of Science ®Google Scholar
• Chan WB, Cockram CS. Panhypopituitarism in association with interferon-alpha treatment. Singapore Med J. 2004;45:93–94.
   PubMedGoogle Scholar
• Concha L, Carlson H, Heimann A. Interferon-induced hypopituitarism. Am J Med. 2003;114:161–163.
   PubMed Web of Science ®Google Scholar
• Ridruejo E. Central hypothyroidism and hypophysitis during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin. Eur J Gastroenterol Hepatol. 2006;18(6):693–694.
   PubMed Web of Science ®Google Scholar
• Sakane N, Yoshida T, Yoshioka K, et al. Reversible hypopituitarism after interferon-alpha therapy. Lancet. 1995;345:1305.
   PubMed Web of Science ®Google Scholar
• Tabben P, Atkinson J, Scheithauer B. Granulomatous adenohypophysitis after interferon and ribavirin therapy. Endocr Pract. 2007;2:169–175.
   Google Scholar
• Ramos-Leví AM, Gargallo M, Serrano-Somavilla A, et al. Hypophysitis following treatment with ustekinumab: radiological and pathological findings. Front Endocrinol (Lausanne). 2018;9:83.
   PubMed Web of Science ®Google Scholar
• Orioli L, Sarti K, Van Den Neste E, et al. Transient hypophysitis in a patient treated by duvelisib for chronic lymphocytic leukemia. Ann Hematol. 2017;96(4):685–686.
   PubMed Web of Science ®Google Scholar
• Anthony J, Esper GJ, Ioachimescu A. Hypothalamic–pituitary sarcoidosis with vision loss and hypopituitarism: case series and literature review. Pituitary. 2016;19(1):19–29.
   PubMed Web of Science ®Google Scholar
• Kapoor E, Cartin-Ceba R, Specks U, et al. Pituitary dysfunction in granulomatosis with polyangiitis: the mayo clinic experience. J Clin Endocrinol Metab. 2014;99(11):3988–3994.
   PubMed Web of Science ®Google Scholar
• De Parisot A, Puéchal X, Langrand C, et al. Pituitary involvement in granulomatosis with polyangiitis: report of 9 patients and review of the literature. Medicine (Baltimore). 2015;94(16):e748.
   PubMed Web of Science ®Google Scholar
• Chu JN, Goglin S, Patzek S, et al. Granulomatosis with polyangiitis presenting as hypophysitis CASE REPORT. Am J Med 2019;132:e21-e22.
   Google Scholar
• Singhai A, Banzal S. Shock: A possible presenting manifestation of autoimmune polyendocrine syndrome type II. Indian J Crit Care Med. 2014;18(5):326.
   PubMedGoogle Scholar
• Katano H, Umemura A, Kamiya K, et al. Visual disturbance by lymphocytic hypophysitis in a non-pregnant woman with systemic lupus erythematosus. Lupus. 1998;7(8):554–556.
   PubMed Web of Science ®Google Scholar
• Ji JD, Lee SY, Choi SJ, et al. Lymphocytic hypophysitis in a patient with systemic lupus erythematosus. Clin Exp Rheumatol. 2000;18(1):78–80.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Asaba K, Tamura K, et al. A case of lymphocytic infundibuloneurohypophysitis associated with systemic lupus erythematosus. Endocr J. 2002;49(6):605–610.
   PubMed Web of Science ®Google Scholar
• Toth M, Szabo P, Racz K, et al. Granulomatous hypophysitis associated with Takayasu’s disease. Clin Endocrinol (Oxf). 1996;45:499–503.
   PubMed Web of Science ®Google Scholar
• Luo C, Lu Y, Jiang L, et al. Castleman’s disease with autoimmune hypophysitis. Acta Neurochir (Wien). 2010;152(10):1811–1812.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Iguchi G, Takeno R, et al. Adult combined GH, prolactin, and TSH deficiency associated with circulating PIT-1 antibody in humans. J Clin Invest. 2011;121(1):113–119.
   PubMed Web of Science ®Google Scholar
• Bando H, Iguchi G, Okimura Y, et al. A novel thymoma-associated autoimmune disease: anti-PIT-1 antibody syndrome. Sci Rep. 2017;7(1):43060.
   PubMedGoogle Scholar
• Yang C, Wu H, Bao X, et al. Lymphocytic hypophysitis secondary to ruptured rathke cleft cyst: case report and literature review. World Neurosurg. 2018;114:172–177.
   PubMed Web of Science ®Google Scholar
• Pekic S, Popovic V. Diagnosis of endocrine disease: expanding the cause of hypopituitarism. Eur J Endocrinol. 2017;79:77–85.
   Google Scholar
• Oishi M, Hayashi Y, Fukui I, et al. Xanthomatous hypophysitis associated with autoimmune disease in an elderly patient: A rare case report. Surg Neurol Int. 2016;7(17):449–453.
   Google Scholar
• de Bruin WI, van ’T Verlaat JW, Graamans K, et al. Sellar granulomatous mass in a pregnant woman with active Crohn’s disease. Neth J Med. 1991;39(3–4):136–141.
   PubMed Web of Science ®Google Scholar
• Freeman HJ, Maguire J. Sellar inflammatory mass with inflammatory bowel disease. Can J Gastroenterol. 2010;24(1):58–60.
   PubMed Web of Science ®Google Scholar
• Da Silva BSP, Bonin C, Bueno CBF, et al. Primary antiphospholipid syndrome and panhypopituitarism: a unique presentation. Acta Reumatol Port. n.d.;37(3):272–275.
   PubMed Web of Science ®Google Scholar
• Caturegli P, Di Dalmazi G, Lombardi, et al. Hypophysitis secondary to Cytotoxic T-Lymphocyte–associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am J Pathol. 2016;186(12):3225–3235.
   PubMed Web of Science ®Google Scholar
• Buxton N, Robertson I. Lymphocytic and granulocytic hypophysitis: a single centre experience. Br J Neurosurg. 2001;15(3):242–5, discussion 245–6.
   Web of Science ®Google Scholar
• Somma T, Solari D, Beer-Furlan, et al. Endoscopic endonasal management of rare sellar lesions: clinical and surgical experience of 78 cases and review of the literature. Wneu. 2017;100:369–380.
   Google Scholar
• Petrakakis I, Pirayesh A, Krauss JK, et al. The sellar and suprasellar region: A “hideaway” of rare lesions. Clinical aspects, imaging findings, surgical outcome and comparative analysis. Clin Neurol Neurosurg. 2016;149:154–165.
   PubMed Web of Science ®Google Scholar
• Angelousi A, Cohen C, Sosa S, et al. Clinical, endocrine and imaging characteristics of patients with primary hypophysitis. Horm Metab Res. 2018;50:296–302.
   PubMed Web of Science ®Google Scholar
• Gutenberg A, Hans V, Puchner MJA, et al. Primary hypophysitis: clinical-pathological correlations. Eur J Endocrinol. 2006;155(1):101–107.
   PubMed Web of Science ®Google Scholar
• Honegger J, Schlaffer S, Menzel C, et al. Diagnosis of primary hypophysitis in Germany. J Clin Endocrinol Metab. 2015;100(10):3841–3849.
   PubMed Web of Science ®Google Scholar
• Kyriacou A, Gnanalingham K, Kearney T. Lymphocytic hypophysitis: modern day management with limited role for surgery. Pituitary. 2017;20:241–250.
   PubMed Web of Science ®Google Scholar
• Bellastella DB. Lymphocytic hypophysitis: a rare or underestimated disease? Eur J Endocrinol. 2003;149(5):363–376.
   PubMed Web of Science ®Google Scholar
• De Bellis A, Bizzarro A, Bellastella A. Pituitary antibodies and lymphocytic hypophysitis. Best Pract Res Clin Endocrinol Metab. 2005;19(1):67–84.
   PubMed Web of Science ®Google Scholar
• De Bellis A, Bizzarrot A, Perrino S, et al. Characterization of antipituitary antibodies targeting pituitary hormone-secreting cells in idiopathic growth hormone deficiency and autoimmune endocrine diseases. Clin Endocrinol (Oxf). 2005;63(1):45–49.
   PubMed Web of Science ®Google Scholar
• De Bellis A, Iacovo D, Bellastella A, et al. Characterization of pituitary cells targeted by antipituitary antibodies in patients with isolated autoimmune diseases without pituitary insufficiency may help to foresee the kind of future hypopituitarism. Pituitary. 2014;17:457–463.
   PubMed Web of Science ®Google Scholar
• Fukuoka H. Hypophysitis. Endocrinol Metab Clin North Am. 2015;44:143–149.
   PubMed Web of Science ®Google Scholar
• Heaney AP, Sumerel B, Rajalingam R, et al. HLA markers DQ8 and DR53 are associated with lymphocytic hypophysitis and may aid in differential diagnosis. J Clin Endocrinol Metab. 2015;100(11):4092–4097.
   PubMed Web of Science ®Google Scholar
• Chiloiro S, Capoluongo ED, Tartaglione T, et al. Human leucocyte antigens coeliac haplotypes and primary autoimmune hypophysitis in caucasian patients. Clin Endocrinol (Oxf). 2018;88(5):692–699.
   PubMed Web of Science ®Google Scholar
• Lupi I, Zhang J, Gutenberg A, et al. From pituitary expansion to empty sella: disease progression in a mouse model of autoimmune hypophysitis. Endocrinology. 2011;152(11):4190–4198.
   PubMed Web of Science ®Google Scholar
• Imber BS, Lee HS, Kunwar S, et al. Hypophysitis: a single-center case series. Pituitary. 2015;18:630–641.
   PubMed Web of Science ®Google Scholar
• Hunn BHM, Martin WG, Simpson S, et al. Idiopathic granulomatous hypophysitis: A systematic review of 82 cases in the literature. Pituitary. 2014;17(4):357–365.
   PubMed Web of Science ®Google Scholar
• Duan K, Asa SL, Winer D, et al. Xanthomatous hypophysitis is associated with ruptured Rathke’s cleft cyst. Endocr Pathol. 2017;28(1):83–90.
   PubMed Web of Science ®Google Scholar
• Joung JY, Jeong H, Cho Y, et al. Steroid responsive xanthomatous hypophysitis associated with autoimmune thyroiditis: a case report. Endocrinol Metab. 2013;28:65–69.
   Google Scholar
• Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344(10):732–738.
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Funata N, Hayashi Y, et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol. 2003;38(10):982–984.
   PubMed Web of Science ®Google Scholar
• Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012;366:539–551.
   PubMed Web of Science ®Google Scholar
• Bando H, Iguchi G, Fukuoka H, et al. The prevalence of IgG4-related hypophysitis in 170 consecutive patients with hypopituitarism and/or central diabetes insipidus and review of the literature. Eur J Endocrinol. 2014;170(2):161–172.
   PubMed Web of Science ®Google Scholar
• Lin W, Lu S, Chen H, et al. Clinical characteristics of immunoglobulin G4–related disease: a prospective study of 118 Chinese patients rheumatology key messages. Rheumatology. 2015;54:1982–1990.
   PubMed Web of Science ®Google Scholar
• Ebbo M, Daniel L, Pavic M, et al. Abdominal systemic disease: igG4-related disease. Jpn J Clini Radiol. 2012;57(2):261–271.
   Google Scholar
• van der Vliet H, Perenboom R. Multiple Pseudotumors in IgG-4 associated multifocal systemic fibrosis. Ann Intern Med. 2004;141:896–897.
   PubMed Web of Science ®Google Scholar
• Wong S, Lam W, Wong W, et al. Hypophysitis presented as inflammatory pseudotumor in immunoglobulin G4 (IgG4) related systemic disease. Hum Pathol. 2007;38:1720–1723.
   PubMed Web of Science ®Google Scholar
• Leporati P, Landek-Salgado MA, Lupi I, et al. IgG4-related hypophysitis: a new addition to the hypophysitis spectrum. J Clin Endocrinol Metab. 2011;96(7):1971–1980.
   PubMed Web of Science ®Google Scholar
• Shikuma J, Kenshi K, Ito R, et al. Critical review of IgG4-related hypophysitis. Pituitary. 2017;20:282–291.
   PubMed Web of Science ®Google Scholar
• Iseda I, Hida K, Tone A, et al. Prednisolone markedly reduced serum IgG4 levels along with the improvement of pituitary mass and anterior pituitary function in a patient with IgG4-related infundibulo-hypophysitis. Endocr J. 2014;61(2):195–203.
   PubMedGoogle Scholar
• Faje A. Hypophysitis: evaluation and Management. Clin Diabetes Endocrinol. 2016;2(1):82–92.
   Google Scholar
• Bernreuther C, Illies C, Flitsch J, et al. IgG4-related hypophysitis is highly prevalent among cases of histologically confirmed hypophysitis. Brain Pathol. 2017;27(6):839–845.
   PubMed Web of Science ®Google Scholar
• Khosroshahi A, Wallace ZS, Crowe JL, et al. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol. 2015;67(7):1688–1699.
   PubMed Web of Science ®Google Scholar
• Caputo C, Bazargan A, Mckelvie PA, et al. Hypophysitis due to IgG4-related disease responding to treatment with azathioprine: an alternative to corticosteroid therapy. Pituitary. 2014;17:251–256.
   PubMed Web of Science ®Google Scholar
• Gu W-J, Zhang Q, Zhu J, et al. Rituximab was used to treat recurrent IgG4-related hypophysitis with ophthalmopathy as the initial presentation: a case report and literature review. Clin Case Rep. 2017;96(24):e6934.
   Google Scholar
• Park SM, Cheol Bae J, Joung JY, et al. Clinical characteristics, management, and outcome of 22 cases of primary hypophysitis. Endocrinol Metab. 2014;29:470–478.
   Google Scholar
• Wang S, Wang L, Yao Y, et al. Primary lymphocytic hypophysitis: clinical characteristics and treatment of 50 cases in a single centre in China over 18 years. Clin Endocrinol (Oxf). 2017;87(2):177–184.
   PubMed Web of Science ®Google Scholar
• Gutenberg A, Larsen J, Lupi I, et al. A radiologic score to distinguish autoimmune hypophysitis from nonsecreting pituitary adenoma preoperatively. Am J Neuroradiol. 2009;30(9):1766–1772.
   PubMed Web of Science ®Google Scholar
• Faje A, Tritos NA, Swearingen B, et al. Neuroendocrine disorders: pituitary imaging. Handb Clin Neurol. 2016;136(873):885.
   Google Scholar
• Iwama S, Sugimura Y, Kiyota A, et al. Rabphilin-3A as a targeted autoantigen in lymphocytic infundibulo-neurohypophysitis. J Clin Endocrinol Metab. 2015;100(7):E946–E954.
   PubMed Web of Science ®Google Scholar
• Takao T, Nanamiya W, Matsumoto R, et al. Antipituitary antibodies in patients with lymphocytic hypophysitis. Hormone Res. 2001;55:288–292.
   PubMedGoogle Scholar
• O’dwyer DT, Smith AI, Matthew ML, et al. Identification of the 49-kDa autoantigen associated with lymphocytic hypophysitis as-enolase. J Clin Endocrinol Metab. 2002;87(2):752–757.
   PubMed Web of Science ®Google Scholar
• Bensing S, Hulting A-L, Hoog A, et al. Lymphocytic hypophysitis: report of two biopsy-proven cases and one suspected case with pituitary autoantibodies. J Endocrinol Invest. 2007;30(2):153–162.
   PubMed Web of Science ®Google Scholar
• Yasuda Y, Iwama S, Kiyota A, et al. Critical role of rabphilin-3A in the pathophysiology of experimental lymphocytic neurohypophysitis. J Pathol. 2018;244(4):469–478.
   PubMed Web of Science ®Google Scholar
• Ricciuti A, De Remigis A, Landek-Salgado MA, et al. Detection of pituitary antibodies by immunofluorescence: approach and results in patients with pituitary diseases. J Clin Endocrinol Metab. 2014;99(5):1758–1766.
   PubMed Web of Science ®Google Scholar
• De Bellis A, Colao A, Di Salle F, et al. A longitudinal study of vasopressin cell antibodies, posterior pituitary function, and magnetic resonance imaging evaluations in subclinical autoimmune central diabetes insipidus. J Clin Endocrinol Metab. 1999;84:3047–3051.
   PubMed Web of Science ®Google Scholar
• De Bellis A, Sinisi AA, Pane E, et al. Involvement of hypothalamus autoimmunity in patients with autoimmune hypopituitarism: role of antibodies to hypothalamic cells. J Clin Endocrinol Metab. 2012;97(10):3684–3690.
   PubMed Web of Science ®Google Scholar
• Khare S, Jagtap VS, Budyal SR, et al. Primary (autoimmune) hypophysitis: a single centre experience. Pituitary. 2015;18:16–22.
   PubMed Web of Science ®Google Scholar
• Honegger J, Buchfelder M, Schlaffer S, et al. Treatment of primary hypophysitis in Germany. J Clin Endocrinol Metab. 2015;100(9):3460–3469.
   PubMed Web of Science ®Google Scholar
• Jian F, Bian L, Sun S, et al. Surgical biopsies in patients with central diabetes insipidus and thickened pituitary stalks. Endocrine. 2014;47:325–335.
   PubMed Web of Science ®Google Scholar
• Chiloiro S, Tartaglione T, Capoluongo ED, et al. Hypophysitis outcome and factors predicting responsiveness to glucocorticoid therapy: a prospective and double-arm study. J Clin Endocrinol Metab. 2018;103(10):3877–3889.
   PubMed Web of Science ®Google Scholar
• Lupi I, Cosottini M, Caturegli P, et al. Diabetes insipidus is an unfavorable prognostic factor for response to glucocorticoids in patients with autoimmune hypophysitis. Eur J Endocrinol. 2017;177(2):127–135.
   PubMed Web of Science ®Google Scholar
• Louvet C, Maqdasy S, Tekath M, et al. Infundibuloneurohypophysitis associated with sjögren syndrome successfully treated with mycophenolate mofetil. Medicine (Baltimore). 2016;95(13):e3132.
   PubMed Web of Science ®Google Scholar
• Lupi I, Manetti L, Raffaelli V, et al. Diagnosis and treatment of autoimmune hypophysitis: A short review. J Endocrinol Invest. 2011;34:245–252.
   Web of Science ®Google Scholar
• Pekic S, Bogosavljevic V, Peker S, et al. Lymphocytic hypophysitis successfully treated with stereotactic radiosurgery: case report and review of the literature. J Neurol Surg A. 2018;79:77–85.
   Google Scholar
• Sawachika H, Kodama S, Mukai T, et al. (2018). Mycophenolate mofetil treatment in a patient with recurrent lymphocytic hypophysitis. Case Report.
   Google Scholar
• Katsiveli P, Sfakiotaki M, Voulgaris N, et al. A complicated case of primary hypophysitis with bilateral intracavernous carotid artery occlusion. Hormones. 2016;15(2):291–296.
   PubMedGoogle Scholar
• Schreckinger M, Francis T, Rajah G, et al. Novel strategy to treat a case of recurrent lymphocytic hypophysitis using rituximab. J Neurosurg. 2012;116(6):1318–1323.
   PubMed Web of Science ®Google Scholar
• Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39:98–106.
   PubMed Web of Science ®Google Scholar
• Dillard T, Yedinak CG, Joshi AE, et al. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary. 2010;13:29–38.
   PubMed Web of Science ®Google Scholar
• Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014;99(11):4078–4085.
   PubMed Web of Science ®Google Scholar
• Min L, Hodi FS, Giobbie-Hurder A, et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res. 2015;21(4):749–755.
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006–2023.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377:1345–1356.
   PubMed Web of Science ®Google Scholar
• De Sousa SMC, Sheriff N, Tran CH, et al. Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis. Pituitary. 2018;21:274–282.
   PubMed Web of Science ®Google Scholar
• Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens a systematic review and meta-analysis. JAMA Oncol. 2018;4(2):173–182.
   PubMed Web of Science ®Google Scholar
• Kanie K, Iguchi G, Bando H, et al. Two cases of atezolizumab-induced hypophysitis. J Endocr Soc. 2018;2(1):91–95.
   PubMed Web of Science ®Google Scholar
• Scott ES, Long GV, Guminski A, et al. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. Eur J Endocrinol. 2018;178(2):173–180.
   PubMed Web of Science ®Google Scholar
• Faje AT, Lawrence D, Flaherty K, et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. 2018;124:1–9.
   Web of Science ®Google Scholar
• Maker AV, Yang JC, Sherry RM, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother. 2006;29(4):455–463.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Vecchio MD, Robert C, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Articles Lancet Oncol. 2017;18:611–633.
   PubMed Web of Science ®Google Scholar
• Lam T, Chan MMK, Sweeting AN, et al. Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series. Intern Med J. 2015;45(10):1066–1073.
   PubMed Web of Science ®Google Scholar
• Iwama S, De Remigis A, Callahan MK, et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014;6(230):1–12.
   Web of Science ®Google Scholar
• Byun DJ, Wolchok JD, Rosenberg LM, et al. Cancer immunotherapy – immune checkpoint blockade and associated endocrinopathies. Nat Publishing Group. 2017;13:195–207.
   PubMed Web of Science ®Google Scholar
• Chang L-S, Barroso-Sousa R, Tolaney SM, et al. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev. 2019;40(1):17–65.
   PubMed Web of Science ®Google Scholar
• Zhao C, Harsha Tella S, Del RJ, et al. Anti-PD-L1 treatment induced central diabetes insipidus. J Clin Endocrinol Metab. 2018;103(2):365–369.
   PubMed Web of Science ®Google Scholar
• Gunawan F, George E, Roberts A. Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies. Endocrinol Diabetes Metab Case Rep. 2018 pii: 17-0146.
   PubMedGoogle Scholar
• Albarel F, Gaudy C, Castinetti F, et al. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol. 2015;172(2):195–204.
   PubMed Web of Science ®Google Scholar
• Min L, Vaidya A, Becker C. Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series. Endocr Pract. 2012;18(3):351–355.
   PubMed Web of Science ®Google Scholar
• Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(11):3888–3921.
   PubMed Web of Science ®Google Scholar
• Torino F, Barnabei A, Paragliola RM, et al. MAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. Eur J Endocrinol. 2013;169(6):153–164.
   PubMed Web of Science ®Google Scholar
• Castinetti F, Albarel F, Archambeaud F, et al. French endocrine society guidance on endocrine side-effects of immunotherapy. Endocr Relat Cancer. 2018 Oct 1. pii: ERC-18-0320.R1. [Epub ahead of print].
   Web of Science ®Google Scholar
• Sarnaik AA, Yu B, Yu D, et al. Cancer therapy: clinical extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res. 2011;17(4):896–906.
   PubMed Web of Science ®Google Scholar
• Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanomatreated by CTL-associated antigen-4 blockade. Cancer Ther Clin. 2007;13:6681–6688.
   PubMed Web of Science ®Google Scholar